Crystalline forms of Venlafaxine hydrochloride were found, referred to
hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention
is directed to processes for the preparation of these crystalline forms and pharmaceutical
compositions comprising the crystalline forms.